Akeso Inc.

Stories

Ivonescimab regimen tops durvalumab in biliary tract cancer trial

Sponsor of HARMONi-GI1; developed ivonescimab

Patients with advanced biliary tract cancer lived a median of 14.9 months on ivonescimab plus chemotherapy, versus 12.1 months on durvalumab (Imfinzi) plus chemo. That is a 25% lower risk of death in the Phase III HARMONi-GI1 trial, which Akeso presented at the ESMO 2026 Presidential Symposium in Madrid on October 25.

Updated Oct 27

AstraZeneca invests $2 billion in Summit Therapeutics for ADC combination strategy

Money Moves

Engineered ivonescimab; retains rights in China

AstraZeneca closed its $2 billion Summit Therapeutics investment on October 5: a straight equity purchase with no royalties or milestones attached, according to Biotech Morning. The cash funds trials pairing Summit's ivonescimab, a bispecific antibody that blocks PD-1 and VEGF, with AstraZeneca's antibody-drug conjugates.

Updated Oct 21